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ABSTRACT
Background and Patients
One of the authors (AL) presented a poster on 34 pregnancies of maternal Lyme 
borreliosis (Lb) in 1995. It was  striking that untreated Lb associated with higher 
probability of adverse outcome but the number of patients were small and the 
statistical power was low (1). We have recently published a paper on 95 maternal 
Lb and the outcome of their pregnancies (2). Since the closure of the database 
for that manuscript the number of the pregnant women with Borrelia infection 
observed in our Centre increased to 124, and the statistical analysis 
strengthened our previous doubtful observations and reached significant results 
in important aspects by now. This series is the largest study to date on this topic. 
Results
Treatment was administered parenterally to 87 (70%) women and orally to 25 
(20.0%). Infection remained untreated in 12 (10%) pregnancies. Adverse 
outcomes were seen in 7/87 (8%), 9/25 (36%), 8/12 (67%), of the parenterally, 
orally treated and untreated women, respectively. In comparison to patients 
treated with antibiotics, untreated women had a significantly higher risk of 
adverse pregnancy outcomes (OR: 11.62, p<0.001). Mothers treated orally 
comparing to iv. treatment had an increased chance (OR: 6.28) to have an 
adverse outcome (p=0.001). In the adverse pregnancy outcome, the most 
impressive difference was between the untreated and parenterally treated women 
(OR: 21.44, p<0.001). The probability of adverse outcome increased by the 
exposition time (from the first maternal symptom to the treatment or delivery). 
When the exposition time has reached four months, the probability of adverse 
outcome increased by 33%. We had no chance to examine the bacterial invasion 
of the foetus. Loss of the pregnancy (N=9), small for gestational age or preterm 
birth (N=7) were the most prevalent adverse outcomes in our series. The other 
complications were heterogeneous.     
Conclusion
Our results indicate that untreated or orally treated maternal Borrelia burgdorferi 
s.l. infection is associated with adverse outcomes. ‘Congenital Lyme disease’ 
similar to the Hutchinson’s triad in syphilis is unlikely. 
INTRODUCTION
Lb is the most frequent vector-borne illness in the temperate zone of the northern 
hemisphere. Early publications suggested that like syphilis, maternal Borrelia 
burgdorferi s.l. infection may seriously influence the outcome of pregnancy. 
Stillbirth and congenital heart abnormalities have been described. With the 
exception of some publications, most early case reports have described patients 
with adverse outcomes following their pregnancies. Incidence and cross sectional 
studies on populations of one to five thousand pregnant women and/or their 
offspring hardly found a case of Lb and, therefore, remained inconclusive with 
respect to risk for adverse pregnancy outcomes.
Epidemiological evaluation of treated and untreated patients is also complicated 
by the low rate of untreated cases present and identified in most populations. 
Almost every patient in the largest study until the present report on gestational Lb 
was treated with ceftriaxone. Many years ago, analysis of our recorded data 
suggested that untreated Lb patients had a much greater chance of suffering an 
adverse outcome in pregnancy, but the number of the patients was too low to 
achieve meaningful results. 
The Center for Tick-borne Diseases, Budapest was opened in 1986 under the 
leadership of one of the authors (AL). Since then, almost 9000 erythema migrans 
(EM) patients were seen, including 124 cases in which Borrelia burgdorferi s.l. 
infection was clinically evident during pregnancy. Here we report our experience 
with these cases.
RESULTS
Almost every mothers showed the typical sign of Lb, i.e. erythema migrans. Three 
had acrodermatitis chronica atrophicans and four had facial palsy with intrathecal 
antibody production (3). We registered 31 adverse outcomes in 24 (19.3%) of the 
124 offspring; these are listed in Table 1.
Treatment was administered parenterally to 87 (70%) women and orally to 25 
(20.0%). Infection remained untreated in 12 (10%) pregnancies.
Adverse outcomes were seen in 7/87 (8%), 9/25 (36%), 8/12 (67%), of the 
parenterally, orally treated and untreated women, respectively.
In comparison to patients treated with antibiotics, untreated women had a 
significantly higher risk of adverse pregnancy outcomes. Mothers treated orally 
comparing to iv. treatment had an increased chance to have an adverse 
outcome. In the adverse pregnancy outcome, the most impressive difference was 
between the untreated and parenterally treated women (Figure 1)
The probability of adverse outcome increased by the exposition time (from the 
first maternal symptom to the treatment or delivery). When the exposition time 
has reached four months, the probability of adverse outcome increased by 33% 
(Figure 2).
There was a higher risk of pregnancy loss if the infection was shortly before or 
after the conception, while other complication were more frequent when the 
infection happened during later in the pregnancy (Figure 3).
We had no chance to examine the bacterial invasion of the foetus.
 
Adverse outcome Number of cases 
- frequency %
Start of infection
in pregnancy weeks 
(average) 
Average incidence in 
Hungary - %
Spontaneous abortion 8 6.4 1-5 (2) 14.8*
Stillbirth 1 0.8 5 0.51*
Premature birth 3 2.4 17-28 (21) 8.2-9.8**
Small for dates (i.u. dystrophy) 4 3.2 13-37 (26) NA
Cavernous hemangioma 3 2.4 13-27 (21) 0.11**
Neonatal jaundice required 
exchange transfusion
2 1.6 13-38 (25) NA
Dysplasia coxae 2 1.6 before conception; 18 0.21**
Pyloric stenosis 2 1.6 before conception; 14 0.02**
Papulovesicular eruption at birth 1 0.8 38 NA
Cerebral bleeding 1 0.8 4 NA
Muscular hypotonicity 1 0.8 4 NA
Hypospadias 1 0.8 27 0.21**
Skeletal anomaly 1 0.8 13 NA
Ectopic kidney 1 0.8 24 0.09-0.12***
Table 1
Adverse outcome in 24 of the 124 pregnancies of maternal Lyme borreliosis 
Some infants were born with multiple anomalies. NA=not available. * Data are from 1996-2006. ** Data are from 1986-
2006. *** Data are from 1992 and 2002.
CONCLUSION
Our findings demonstrate a statistically significant association between 
untreated Lyme borreliosis and adverse outcome of pregnancy. Many 
controversial papers have been published and we think that our study is the first 
in which sufficiently heterogeneous and large numbers of mothers were 
gathered for statistical evaluation. 
It seems that a specific syndrome representing a ‘congenital Lyme borreliosis’ is 
unlikely. However, spontaneous abortion, stillbirth and preterm birth are 
frequently published in other studies and also in our series. Pregnancy loss was 
significantly more frequent amongst untreated patients than among the 
parenterally treated women in our study population. 
During the last 18 years, intravenous ceftriaxone was preferred to treatment 
with oral amoxicillin in our practice. During pregnancy, amoxicillin has lower 
plasma concentrations and more rapid elimination than in the postpartum or 
non-pregnant situation. The pharmacokinetics of ceftriaxone, however, is not 
significantly influenced by pregnancy. In addition, ceftriaxone in vitro is more 
effective against Borrelia than other beta-lactams.
Our present data are definitively support the superiority of high dose iv. penicillin 
or parenterally administered ceftriaxone over the oral antibiotic treatment. We 
had no chance to examine the placenta or fetus for direct borrelia invasion in 
the cases of pregnancy loss, therefore the causal relation remains opened in 
spite of the statistical association. 
Figure 1.
Risk of adverse pregnancy outcome in 
various comparisons of treatment 
groups
The red boxes represent the odds ratio 
(OR), the horizontal grey line are the 95% 
confidence intervals of estimation. The 
vertical grey line means the OR=1, ie. 
there is no difference in the odds of the 
compared groups. If the confidence 
interval contains the value OR=1, then the 
estimation is not significant on the certain 
level (p<0.05). The size of the red boxes is 
proportional to the precision of estimation. 
Figure 2
Probability of the adverse pregnancy outcome in 
maternal Lyme borreliosis and the Borrelia 
exposition length (month) of the fetus
The individual outcomes are represented as jittered dots 
around 0 (no adverse outcome) and 1 (adverse 
outcome).
Figure 3
Association plot of pregnancy outcome and the 
time of appearance (trimester) of the symptom
The differences (Pearson's residuals) between the 
observed and expected frequencies of contingency 
table are presented with rectangles. Height and width of 
the bars are proportional to Pearson's residuals, and 
the expected counts, respectively. If the observed 
frequency of a cell is greater than the expected one, the 
box rises above the baseline, and falls below otherwise.
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